Swiss pharmaceutical giant Roche has finalised a £4.4 billion deal with Danish biotech firm Zealand Pharma to develop and commercialise a next-generation obesity treatment. The agreement focuses on Petrelintide, a
Swiss pharmaceutical giant Roche has finalised a £4.4 billion deal with Danish biotech firm Zealand Pharma to develop and commercialise a next-generation obesity treatment. The agreement focuses on Petrelintide, a






